NCT05588609 2025-09-18
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Merus B.V.
Phase 2 Terminated
Clinical Trials
6 trialsNCT02122172 2025-04-25
Afatinib in Advanced Refractory Urothelial Cancer
University of Chicago
Phase 2 Terminated
NCT02795156 2023-12-05
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01320280 2022-07-01
BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Terminated
NCT02780687 2020-11-18
LUX-Bladder 1
Boehringer Ingelheim
Phase 2 Completed
NCT00706628 2015-01-15
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed